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The G-protein-coupled receptor (GPCR) superfamily, which includes somatostatin receptors (SSTRs), is one of the
most important drug targets in the pharmaceutical industry. The yeast Saccharomyces cerevisiae is an attractive host
for the ligand screening of human GPCRs. Here, we demonstrate the utility of the technology that was developed
for displaying peptide ligands on yeast plasma membrane, termed “PepDisplay”, which triggers signal transduction
upon GPCR activation. A yeast strain that heterologously produced human somatostatin receptor subtype-2 (SSTR2)
and chimeric Gα protein was constructed along with membrane-displayed somatostatin; somatostatin was
displayed on the yeast plasma membrane by linking it to the anchoring domain of the glycosylphosphatidylinositol
anchored plasma membrane protein Yps1p. We demonstrate that the somatostatin displayed on the plasma
membrane successfully activated human SSTR2 in S. cerevisiae. The methodology presented here provides a new
platform for identifying novel peptide ligands for both liganded and orphan mammalian GPCRs.
Keywords: Membrane-displayed ligand, PepDisplay, Yeast GPCR assay, Cyclic peptide, Somatostatin receptor
subtype-2, Chimeric Gα proteinIntroduction
G-protein-coupled receptors (GPCRs) are proteins that
possess seven transmembrane domains and constitute
one of the largest gene families in the human genome
(Jacoby et al. 2006). More than 50% of all drugs, with
annual worldwide sales exceeding $50 billion, regulate
GPCR functions, and approximately 30% of these drugs
directly target GPCRs (Hopkins and Groom 2002; Xiao
et al. 2008). Although the human genome contains
720–800 GPCRs (Siehler 2008), it is still less than 50
GPCRs that are the targets of commercially available
drugs (Eglen et al. 2007). The development of a robust, re-
liable, and cost-effective functional screening method for
both known and orphan GPCRs is a major focus of the
pharmaceutical industry (Thomsen et al. 2005). Accord-
ingly, it is evident that the market for the discovery and
development of drugs targeting GPCRs will continue to
grow in the coming decade.* Correspondence: miueda@kais.kyoto-u.ac.jp
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in any medium, provided the original work is pA GPCR assay that uses the baker’s yeast Saccharo-
myces cerevisiae has been established as an experimental
system for characterizing human receptor pharmacology
and signal transduction mechanisms (Dowell and Brown
2002). Its attractive features are its simplicity with re-
spect to genetic manipulation, economical propagation,
easy maintenance of stably expressing cell lines, availabil-
ity of an evolutionarily highly conserved signaling path-
way, and presence of only two endogenous GPCRs that
can be readily eliminated (Ladds et al. 2005). In spite of
the major differences in G-proteins and membrane lipid
composition between yeasts and mammalian cells, nu-
merous cases of successful production of functional
mammalian GPCRs in yeast have been documented (Xue
et al. 2008). In addition, yeasts are attractive hosts for the
high throughput screening of peptides or proteins from
large combinatorial libraries (Chao et al. 2006; Li et al.
2007; Ueda 2004), with a high transformation efficiency
of plasmids of up to 1–1.5 × 108 transformants/μg
achieved (Benatuil et al. 2010). Furthermore, homologous
recombination (Ito et al. 2008), also known as gap-repair
cloning, can be employed in yeast, which supports theOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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mid libraries.
The membrane-tethered peptide ligand is rather a new
concept that was first documented by Fortin et al. (2009).
In yeast, the display of heterologous peptides or proteins
on cell wall was established by fusion with a part of cell
wall proteins (Ueda and Tanaka 2000). However, it is con-
sidered that the displayed peptide ligand needs to
localize within the range allowing the access to
membrane-localized GPCRs. Therefore, we displayed
the peptide ligand on the plasma membrane rather
than cell wall, by using an anchoring domain of the
glycosylphosphatidylinositol (GPI)-anchored plasma mem-
brane protein, Yps1p. In the previous study, the α-factor,
which is a 13-amino acid residue-long peptide agonist of
the yeast pheromone response pathway, was successfully
displayed on the yeast plasma membrane, and signal acti-
vation was observed by employing a fluorescent reporter
gene assay (Hara et al. 2012a). Extended application of this
system to human GPCRs, which comprise one of the most
important types of drug targets that are being pursued
today, would be a valuable technology.
Somatostatin is a naturally occurring gastrointestinal
hormone that regulates various endocrine and exocrine
processes (Patel 1999). It is a cyclic tetradecapeptide
with a disulfide bond between Cys3 and Cys14 residues.
Cyclic peptides are promising scaffolds for peptide thera-
peutics because cyclic structures increase not only the
physiological (serum) stability of peptides but also their
affinity for binding partners owing to their conform-
ational rigidity (Katoh et al. 2011). In fact, somato-
statin receptor ligands, most of which possess cyclic
structures, have been widely used as safe and effective
treatments for pituitary and neuroendocrine tumors
(Low 2004; Patel 1999; Weckbecker et al. 2003). The
effects of somatostatin are transduced by its binding to
plasma membrane-localized somatostatin receptors
(SSTRs). SSTRs are encoded by five subtypes (SSTRx;
x = 1–5) and compose a subset of the GPCR super-
family (Jacoby et al. 2006).
In this study, the range of application of our technol-
ogy for displaying peptide ligands on yeast plasma mem-
branes, namely “PepDisplay”, was extended to the
activation of human GPCR that was heterologouslyTable 1 List of yeast strains used and constructed in this stud
Strain Genotype
W303-1A MATa; ade2-1; his3-11,15; leu2-3,112; trp1-1; ura3-1
WH-3 MATa; ade2-1; his3-11,15; leu2-3,112; trp1-1; ura3-1; sst2Δ; far1Δ
WH-7 MATa; ade2-1; his3-11,15; leu2-3,112; trp1-1; ura3-1; sst2Δ; far1Δ; ste
WH-9 MATa; ade2-1; his3-11,15; leu2-3,112; trp1-1; ura3-1; sst2Δ; far1Δ; ste
WSTH-9 MATa; ade2-1; his3-11,15; leu2-3,112; trp1-1; ura3-1; sst2Δ; far1Δ; ste
pYEXfetproduced in S. cerevisiae. The methodology presented in
this study could be useful for identifying novel peptide
ligands for both liganded and orphan mammalian GPCRs.Materials and methods
Strains and media
The haploid yeast (S. cerevisiae) strain W303-1A (MATa,
ade2-1, his3-11,15, leu2-3,112, trp1-1, ura3-1) (Thomas
and Rothstein 1989), and other strains that were con-
structed specifically for our study, and their genotypes
are listed in Table 1. The yeast strains were cultivated
aerobically in YPD medium (1% [w/v] yeast extract, 2%
[w/v] peptone, and 2% [w/v] glucose), or in synthetic
complete (SC) medium lacking histidine, adenine, leucine,
and tryptophan (SC-HALW), containing 0.67% (w/v) yeast
nitrogen base without amino acids, 2% glucose, Multiple
Drop-outs (DSCK292; ForMedium, Norfolk, UK), and
appropriate amino acids. The assay medium was buffered
at pH 7.2 with 50 mM PIPES. Agar (2% [w/v]) was added
to produce YPD and SC solid media. Escherichia coli
DH5α (Toyobo, Osaka, Japan) was used as the host for re-
combinant DNA manipulation and grown in Luria–Bertani
medium (1% [w/v] tryptone, 0.5% [w/v] yeast extract, and
0.5% [w/v] sodium chloride) containing 100 μg·mL-1
ampicillin. After selection, a single colony was used to
isolate the plasmid for transforming the yeast.Expression vectors
PCR was performed using KOD-Plus-DNA polymerase
(Toyobo).
Multistep construction of the SSTR2 expression
plasmid, p412-SSTR2, was initiated by inserting an SacI-
KpnI fragment of the GPD promoter and CYC1 termin-
ator from p413-GPD (Mumberg et al. 1995) into SacI
and KpnI sites in pRS412 (Brachmann et al. 1998) to
create p412-GPD. The DNA fragment encoding
human SSTR2 was amplified from a human brain cDNA
library (B1234035; BioChain, Hayward, CA, USA) with
primers 50-CGCggatccAAAAAAATGGACATGGCGGA
TGAGC-30 and 50-TGCGgtcgacTCAGATACTGGTTT
GGAGGTCTC-30. This fragment was inserted into
the BamHI and SalI sites of p412-GPD to create
p412-SSTR2.y
Reference
(Thomas and Rothstein 1989)
(Hara et al. 2012a)
2Δ Present study
2Δ; gpa1Δ; p413-GPA1(Gi2) Present study
2Δ; gpa1Δ; p413-GPA1(Gi2), p412-SSTR2, Present study
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(Gi2), was constructed as follows. The DNA fragment that
consists of the GPA1 promoter and the GPA1 ORF was




This chimeric Gα-encoding sequence was inserted into the
SacI and XhoI sites of p413-CYC (Mumberg et al. 1995),
from which the SacI-XhoI fragment of the CYC promoter
was removed, to create p413-GPA1(Gi2).
Plasmids for producing membrane-displayed somato-
statin with different linker lengths (Table 2) were con-
structed as follows. DNA fragments with different linker
lengths were amplified from pYS0 (Hara et al. 2012a)
using the following primers: 50-GCGggatccGGTGGA
TCTGATTACAAGGATGACGATGACAAG-30, where
the underlined linker sequence varied depending on the
linker length (namely, (GGTGGATCT)nGGT (n = 0, 1,
2, 3, 4, 7, 13) for linker length 1, 4, 7, 10, 13, 22, 40;
(GGTGGATCT)nGGTGGA (n = 0, 1, 2, 3, 6) for linker
length 2, 5, 8, 11, 20; (GGTGGATCT)n (n = 1, 2, 3, 4, 5,
7, 10) for linker length 3, 6, 9, 12, 15, 21, 30), and 50-
TGGCCGAgtcgacTCAGATGAATGCAAAAAGAAGA
GAAATTAATG-30. The fragments were then inserted
into the BamHI and SalI sites of pYS0, resulting in
plasmids pYS1, pYS2, pYS3, pYS4, pYS5, pYS6, pYS7,
pYS8, pYS9, pYS10, pYS11, pYS12, pYS13, pYS15,
pYS20, pYS21, pYS22, pYS30, and pYS40. Next, a DNA
fragment encoding the glucoamylase secretion signal
and somatostatin was amplified from pULD1 (Kuroda




was inserted into the KpnI and BamHI sites of the
plasmids above. The resulting plasmids were designated
pYS0-sst, pYS1-sst, pYS2-sst, pYS3-sst, pYS4-sst,Table 2 Constructed plasmids for membrane display of
somatostatin in this study
Plasmid Description
pYSn-sst (n = 0, 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 15,
20, 21, 22, 30, 40)
Membrane display of somatostatin
with FLAG tag and various
linker lengths
pYS0-nega Membrane display of FLAG tag
(same construct as pYS0-sst
but lack somatostatin sequence,










with FLAG tagpYS5-sst, pYS6-sst, pYS7-sst, pYS8-sst, pYS9-sst,
pYS10-sst, pYS11-sst, pYS12-sst, pYS13-sst, pYS15-
sst, pYS20-sst, pYS21-sst, pYS22-sst, pYS30-sst, and
pYS40-sst, respectively. Additionally, the DNA frag-
ment encoding the glucoamylase secretion signal se-
quence, but lacking the somatostatin sequence, was
amplified similarly with primers 50-CGGggtaccATG
CAACTGTTCAATTTGCCATTG-30 and 50-CGCggatc
cACCGGCAGAAACGAGCAAAGAAAAGTAAG-30. It
was then inserted into the KpnI and BamHI sites in pYS0.
The resulting plasmid was named pYS0-nega and was
used as a negative control (Table 2).
Plasmids for producing membrane-displayed somato-
statin without FLAG tag (Table 2) were constructed as
follows. DNA fragments that encoded the linker region
and the anchoring domain of Yps1p were amplified from








GAAGAGAAATTAATG-30. The fragments were then
inserted into the BamHI and SalI sites of pYS0-sst, resulting
in plasmids pYS-notag3-sst, pYS-notag20-sst, and pYS-
notag38-sst.
Plasmids for producing membrane-displayed som-
atostatin with an alanine substitution (Table 2) were
constructed as follows. A DNA fragment encoding
the glucoamylase secretion signal and the modified







and was inserted into the KpnI and BamHI sites in
pYS21, generating the plasmids pYS21-sst (W8A)
and pYS21-sst(C14A), respectively.
Construction of yeast strains
All yeast transformation procedures were conducted
with a Frozen-EZ Yeast Transformation-II kit (Zymo Re-
search Corporation, Irvine, CA, USA). The yeast strains
used and constructed in this study are listed in Table 1.
The WH-7 strain, which carried SST2, FAR1, and
STE2 disruptions, was obtained using the 2-step procedure
described by Gueldener et al. (2002) as follows. The
STE2 of strain WH-3 (Hara et al. 2012a) was disrupted
using the loxP-URA3-loxP cassette, which had been ampli-
fied from pUG72 (Gueldener et al. 2002) with the primers




TTTGAgcataggccactagtggatctg-30. Next, Ura- derivatives
of the transformants were selected on media containing 5-
fluoroorotic acid (Boeke et al. 1987). STE2 disruption at
the targeted locus and removal of URA3 were verified by
PCR using appropriate primers. GPA1 disruption was con-
ducted after introduction of p413-GPA1(Gi2) into the
WH-7 strain because the absence of the Gα protein
causes constitutive activity due to the existence of free
Gβγ subunits (Guo et al. 2003). The GPA1 of WH-7 with
p413-GPA1(Gi2) was disrupted using the KanMX4 cas-
sette that had been amplified from the genomic DNA
of strain BY4741 gpa1Δ (EUROSCARF, Frankfurt, Ger-
many) with the primers 50-ACAAGATCATAGGTGGA
TAAAGCAAGCCG-30 and 50-GCCTAGTAGATCTTGA
TTCTTTGTCACCTC-30, to create strain WH-9. The
WH-9 strain was transformed with p412-SSTR2 and a sig-
nal detection plasmid (pYEX-fet (Hara et al. 2012a)),
resulting in the strain WSTH-9. The WSTH-9 strain was
transformed with one of the plasmids for producing mem-
brane-displayed somatostatin.
Cultivation conditions
To prepare starter cultures, a series of WSTH-9 strains
with one of the membrane-displayed ligand plasmids
was grown in 10 mL of SC-HALW medium (pH 7.2) at
30°C overnight. The cultures used for assays were
initiated by inoculating the starter culture into 10 mL
SC-HALW medium to give an initial optical density
(OD) of 0.05 at 600 nm using a VMax Kinetic ELISA
Microplate Reader (Molecular Devices, Sunnyvale, CA,
USA). These cultures were grown at 30°C on a rotary
shaker (250 rpm) until the OD600 reached 0.5–0.6 corre-
sponding to the late log phase.
For signal activation by exogenously added somato-
statin, WSTH-9 strains (without the membrane-
displayed ligand plasmid) were cocultured with serial
dilutions of somatostatin, which was added at the start
of the main culture. These cultures were also grown at
30°C on a rotary shaker (250 rpm) until the OD600
reached 0.5–0.6 corresponding to the late log phase.
Plate assay
Two-hundred microliters of the main cultures with
OD600 ranging over 0.5–0.6 were transferred to a 96-
well plate (353072; BD Falcon, BD Biosciences, San
Diego, CA, USA), and the fluorescence emitted was
measured with a Fluoroskan Ascent Fluorometer (Lab-
systems OY, Helsinki, Finland). A filter pair with an exci-
tation wavelength at 485 nm and emission wavelength at
527 nm was used to detect the fluorescence of enhanced
green fluorescent protein (EGFP) produced in the yeastcells. The OD600 of each well of the sample plate was
measured simultaneously. In order to normalize the
number of cells in each well, the fluorescence value was
divided by the OD600 reading. The fluorescence of the
negative control (pYS0-nega strain, see subsection on
Expression vectors) was subtracted from those for all of
the other samples.
Western blot analysis
A cell membrane fraction was prepared according to the
previously described method (Frieman and Cormack
2004; Hara et al. 2012a). Membrane proteins were ana-
lyzed by electrophoresis on 15% (w/v) SDS polyacryl-
amide gels and electrotransferred onto a nitrocellulose
membrane (Bio-Rad, Richmond, CA, USA). The mem-
brane was pretreated with 5% (w/v) skim milk powder in
PBS (pH 7.4), overnight, for preventing the nonspecific
binding of antibody. The membrane was incubated
for 1 h at room temperature with mouse anti-FLAG
M2-Peroxidase antibody (Sigma-Aldrich, St Louis, MO,
USA) at a concentration of 1:10000 in 5% skim milk/PBS.
The blots were washed 5 times in 2% (v/v) Tween/PBS for
5 min, and antibody binding was detected using ECL-Plus
(GE Healthcare, Buckinghamshire, UK).
Results
An overview of this study is illustrated in Figure 1. To
optimize the signal output, gene deletions were per-
formed on the negative regulator of Gpa1 activity (sst2Δ)
and a cyclin-dependent kinase inhibitor (far1Δ). For the
production of human SSTR2 and chimeric Gα subunit,
gene deletions were performed on yeast endogenous
GPCR (ste2Δ) and G-protein α-subunit (gpa1Δ) accom-
panied by the introduction of human SSTR2 expression
plasmid and chimeric Gα expression plasmid (Brown
et al. 2000; Hara et al. 2012b). The chimeric Gα subunit
employed in this study was the “transplant” type, in
which the C-terminal five amino acids of Gpa1p (KIGII)
were exchanged with the mammalian Gi sequence
(DCGLF). Signal activation was detected by fluorescence
from pYEX-fet (Hara et al. 2012a), which is the high
copy number reporter plasmid that contains EGFP and
is controlled by the signal responsive FUS1 promoter.
When the constructed WSTH-9 strain (Table 1) was
exposed to exogenously added somatostatin, signal ac-
tivation was observed in a dose-dependent manner
(Figure 2), indicating that the chimeric Gα and human
SSTR2 that were heterologously produced in the yeast
were functional.
We introduced plasmids for the membrane display of
somatostatin with different linker lengths into the
WSTH-9 strain. The fluorescence intensity and OD600
of the cell culture were measured at the late log phase,
and the fluorescence intensities of each strain divided by
Figure 1 Schematic representation of signal activation of human somatostatin receptor subtype-2 by membrane-displayed
somatostatin. A. Overview of this study. Membrane-displayed somatostatin (cyclic peptide) activates human somatostatin receptor subtype-2,
which is heterologously produced in yeast, and leads to the activation of chimeric Gα proteins, the mitogen-activated protein kinase cascade,
and transcription factor Ste12p. Phosphorylated Ste12p induces the overexpression of enhanced green fluorescent protein by binding to a
pheromone response element in the FUS1 promoter of pYEX-fet (signal detection plasmid) (Hara et al. 2012a). This expression allows monitoring
and quantification of signal transduction by fluorescence. B. Functional domains encoded by the membrane-displayed somatostatin plasmid.
After processing by the secretory pathway, the signal sequence and glycosylphosphatidylinositol (GPI) targeting sequence are cleaved, and the
somatostatin sequence, with a free N-terminus is displayed on the plasma membrane by GPI covalently linked to the C-terminus. C. Amino-acid
sequence of membrane-displayed somatostatin without FLAG tag.
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broad spectrum of activities in a series of yeast strains
that possessed one of the membrane-displayed somato-
statin plasmids, a strain with pYS21-sst exhibited the
strongest signal (Figure 3A). In addition, the production
of membrane-displayed somatostatin with various linker
lengths on the yeast plasma membrane was confirmed
by western blot analysis of the membrane fraction using
anti-FLAG tag antibody (Figure 3B). These resultsindicate that the membrane-displayed somatostatin dir-
ectly activated the human SSTR2.
To confirm whether the signal activation triggered
by the membrane-displayed somatostatin was due to
the displayed somatostatin, alanine substitution into
somatostatin was employed (Figure 3C). Trp8 is critic-
ally important for agonistic activity and alanine sub-
stitution at Trp8 causes a significant loss in activity
(Rosenthal et al. 1983; Vale et al. 1978). When Trp8 of
Figure 2 Activation of human somatostatin receptor subtype-2
produced in yeast by exogenously added somatostatin. Human
somatostatin receptor subtype-2 was produced in yeast and
stimulated by exogenously added somatostatin at various
concentrations. The fluorescence intensity derived from receptor
activation induced by enhanced green fluorescent protein was
measured by using a 96-well fluorescent plate reader. Each data
point represents the data (mean ± standard error of the mean) of
three independent experiments.
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substituted by alanine, the activity was significantly
decreased (Figure 3C). This indicates that the activation
was triggered by the somatostatin that was displayed on
plasma membrane. Somatostatin is a naturally occurring
cyclic peptide hormone with a disulfide bond between
Cys3 and Cys14 residues. It has been reported that the
hormonal activity was lost in a linearized form of
somatostatin (Vale et al. 1978). To confirm that the
membrane-displayed somatostatin retained its cyclic
structure, the alanine-substituted form of membrane-
displayed somatostatin at Cys14 was also constructed.
Figure 3C shows that the strain harboring pYS21-sst
(C14A) significantly lost its activity, suggesting that the
membrane-displayed somatostatin had a cyclic structure
with a disulfide bond between Cys3 and Cys14 residues.
From the results of Figure 3A, the signal intensity of
each strain depended on the linker length. One of the
reasons for this linker length dependence could be the
FLAG tag sequence (DYKDDDDK), which possesses a
negatively charged sequence. It is possible that this re-
gion interacts with the relatively polar amino acids on
the outer loop of GPCRs, which could give rise to linker
dependency. Considering that the linker dependency
observed in Figure 3A influences the robustness of this
technology, membrane-displayed somatostatins without
a FLAG tag were constructed to overcome this problem.
The linker lengths between somatostatin and the
membrane-anchoring domain of Yps1p were designed to
have 3, 20, and 38 amino acids (pYS-notag3-sst, pYS-
notag20-sst, and pYS-notag38-sst, respectively). Regard-
less of the linker lengths, the membrane-displayed soma-
tostatins without FLAG tag had activity similar topYS21-sst (Figure 3D). This indicates that the negatively
charged nature or the secondary structure of the FLAG
tag region could have resulted in the linker dependency
shown in Figure 3A, and that removal of FLAG tag led
to the reduction of linker dependency of this system.
Discussion
We applied our technology for displaying peptide ligands
on a plasma membrane to human SSTR2 that was het-
erologously produced in yeast cells. Functional activation
of the pheromone response pathway by the membrane-
displayed somatostatin was successfully achieved. In
spite of the previous reports of the functional production
of rat SSTR2 (Price et al. 1995) and human SSTR5
(Fukuda et al. 2011) in yeast, this is the first report that
documents the functional production of human SSTR2
in yeast. While cell wall trapping of autocrine peptides
strategy, in which peptide ligands were displayed on
yeast cell wall, has recently been reported (Ishii et al.
2012), the percentage of activated cells by the system
was lower than that by our system (Hara et al. 2012a).
This suggests that plasma membrane is more suitable
than cell wall in terms of peptide-ligand display. The
higher accessibility of membrane-displayed ligands to
GPCRs may be important for efficient activation. Here,
we termed “PepDisplay” as a technology for displaying
peptide ligands on a plasma membrane for activation of
either endogenous or heterologous GPCRs produced in
yeast cells.
In order to estimate the signal intensity triggered by
the membrane-displayed somatostatin, the signal inten-
sity of strain pYS-notag38-sst was compared with that of
exogenously added somatostatin treatment (Figure 2).
The signal intensity was found to be 86.6% of the max-
imum response of the exogenously added somatostatin
treatment (data not shown). Considering that tethered
peptide-induced signal activation ranged from 35% to
100% of the soluble hormone-induced maximum inten-
sity in a mammalian experimental system (Fortin et al.
2009), the intensity obtained in this study is reasonable.
Although the signal intensity can be improved by further
scrutiny (e.g., length and amino-acid composition of the
linker region, and expression level of the membrane-
displayed ligand), the signal intensity obtained by pYS-
notag38-sst was sufficient for detection and sorting by
fluorescence-activated cell sorter (Hara et al. 2012a).
To the best of our knowledge, the functional display of
cyclic peptides on the plasma membrane has not been
previously reported although several research groups
have reported on membrane-tethered ligands (Chang
et al. 2009; Choi et al. 2009; Fortin et al. 2011; Fortin
et al. 2009). Cyclic peptides comprise a promising type
of scaffold for peptide therapeutics (Katoh et al. 2011),
and the linker dependency of PepDisplay was solved by
Figure 3 Activation of human somatostatin receptor subtype-2 by membrane-displayed somatostatin. A. Fluorescence intensity of yeast
strains transformed with membrane-displayed somatostatin plasmids. A series of yeast strains with one of the membrane-displayed ligand
plasmids was assayed in the late-log phase using a 96-well fluorescent plate reader. Yeast cells harboring pYS21-sst emitted strong fluorescence.
Each data point represents data (mean ± standard error of the mean) of three independent experiments. B. Western blot analysis of a series of
membrane-displayed somatostatins. Production of membrane-displayed somatostatin on yeast plasma membranes was confirmed by western
blot analysis using anti-FLAG tag antibody. The positions of 8.5 and 12 kDa of size markers are indicated by black bars. C. Fluorescence intensity
of yeast strains transformed with plasmids for membrane-displayed somatostatin with alanine substitution. Each data point represents data (mean
± standard error of the mean) of three independent experiments. D. Linker dependency of membrane-displayed somatostatin without FLAG tag
upon receptor activation. Fluorescence intensity of yeast strains transformed with plasmids for membrane-displayed somatostatin without FLAG
tag. Each data point represents data (mean ± standard error of the mean) of three independent experiments.
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sented here will provide a new platform for identifying
novel peptide ligands for both liganded and orphan
mammalian GPCRs.
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